Vaccinex, Inc. financial data

Symbol
VCNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1895 Mount Hope Ave, Rochester, New York
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 67.1 % -69.7%
Return On Equity 1.11K %
Return On Assets -446 % -25.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.73M shares -97.4%
Common Stock, Shares, Outstanding 1.58M shares -97.1%
Entity Public Float 10.4M USD -58.7%
Common Stock, Value, Issued 1K USD -85.7%
Weighted Average Number of Shares Outstanding, Basic 1.82M shares +532%
Weighted Average Number of Shares Outstanding, Diluted 1.82M shares +532%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 232K USD
Research and Development Expense 15M USD -6.69%
General and Administrative Expense 7.02M USD +3.67%
Costs and Expenses 22M USD -3.62%
Operating Income (Loss) -21.6M USD +1.62%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.8M USD +18.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -17.8M USD +18.8%
Earnings Per Share, Basic -4.29 USD/shares +97%
Earnings Per Share, Diluted -4.29 USD/shares +97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 233K USD -87.8%
Accounts Receivable, after Allowance for Credit Loss, Current 1.05M USD +9400%
Assets, Current 2.2M USD -17.8%
Property, Plant and Equipment, Net 106K USD -40.1%
Operating Lease, Right-of-Use Asset 59K USD -74.2%
Assets 2.37M USD -23.3%
Accounts Payable, Current 3.24M USD +102%
Employee-related Liabilities, Current 350K USD +4.17%
Accrued Liabilities, Current 1.75M USD +14.2%
Contract with Customer, Liability, Current 12K USD
Liabilities, Current 5.23M USD +54.6%
Operating Lease, Liability, Noncurrent 21K USD -88.8%
Liabilities 5.23M USD +49.1%
Retained Earnings (Accumulated Deficit) -349M USD -5.35%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.86M USD -577%
Liabilities and Equity 2.37M USD -23.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.63M USD +8.1%
Net Cash Provided by (Used in) Financing Activities 6.07M USD +200%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 1.58M shares -97.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44M USD
Deferred Tax Assets, Valuation Allowance 110M USD +6.6%
Deferred Tax Assets, Gross 110M USD +6.6%
Operating Lease, Liability 59.3K USD -74.1%
Depreciation 110K USD -36.4%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.8M USD +18.8%
Property, Plant and Equipment, Gross 7.25M USD -3.26%
Operating Lease, Liability, Current 59K USD -64.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 868 USD -92.5%
Deferred Tax Assets, Operating Loss Carryforwards 78.5M USD +3.6%
Preferred Stock, Shares Issued 10 shares
Preferred Stock, Shares Authorized 10M shares
Operating Lease, Payments 45.1K USD 0%
Preferred Stock, Shares Outstanding 10 shares
Operating Leases, Future Minimum Payments, Due in Two Years 331K USD +128%
Share-based Payment Arrangement, Expense 427K USD -18%
Operating Leases, Future Minimum Payments Due 60.2K USD -75%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares